The study of neurotransmitter interactions using positron emission tomography and functional coupling

被引:17
作者
Schloesser, R
Simkowitz, P
Bartlett, EJ
Wolkin, A
Smith, GS
Dewey, SL
Brodie, JD
机构
[1] NYU MED CTR,DEPT PSYCHIAT,NEW YORK,NY 10016
[2] NEW YORK VET ADM MED CTR,PSYCHIAT SERV,NEW YORK,NY
[3] BROOKHAVEN NATL LAB,DEPT CHEM,UPTON,NY 11973
关键词
brain imaging; positron emission tomography; schizophrenia; neurotransmitter; interaction; neuroleptic;
D O I
10.1097/00002826-199619050-00001
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Functional brain imaging with positron emission tomography (PET) has opened up new avenues for the investigation of possible functional disturbances related to psychiatric disease as well as pharmacodynamic assessment of drug treatment in vivo, Different strategies to study pharmacologic effects on the brain have been developed in recent years. The basic methods are to measure (a) blood flow or glucose metabolism, (b) parameters of specific receptor binding, or (c) neurotransmitter metabolism. Each of these can be performed either in a resting state or after perturbation with a pharmacologic challenge. Our group has developed a general strategy for investigating pharmacologic effects on brain function: (a) determining indirect drug-induced metabolic changes with fluorodeoxyglucose PET and (b) characterizing functional interactions of neurotransmitter systems by assaying drug-induced displacement of specific receptor ligands. These study designs reflect a paradigm shift where functional coupling of brain regions and interaction of different neurotransmitter systems are seen as the basis for a multitransmitter hypothesis of schizophrenia. In this view, any disturbance in the self-regulatory process is reflected in the loss of functional interaction between systems, An overview of recent studies and their possible clinical importance will be presented.
引用
收藏
页码:371 / 389
页数:19
相关论文
共 120 条
[11]   IMPORTANCE OF PHARMACOLOGICAL CONTROL IN PET STUDIES - EFFECTS OF THIOTHIXENE AND HALOPERIDOL ON CEREBRAL GLUCOSE-UTILIZATION IN CHRONIC-SCHIZOPHRENIA [J].
BARTLETT, EJ ;
WOLKIN, A ;
BRODIE, JD ;
LASKA, EM ;
WOLF, AP ;
SANFILIPO, M .
PSYCHIATRY RESEARCH-NEUROIMAGING, 1991, 40 (02) :115-124
[12]  
BIVER F, 1994, EUR J NUCL MED, V21, P937
[13]  
BUCHSBAUM MS, 1982, ARCH GEN PSYCHIAT, V39, P251
[14]  
BUCHSBAUM MS, 1992, NEUROPSYCHOPHARMACOL, V6, P155
[15]  
Bunney B S, 1976, Res Publ Assoc Res Nerv Ment Dis, V55, P249
[16]   SCHIZOPHRENIA - A SUBCORTICAL NEUROTRANSMITTER IMBALANCE SYNDROME [J].
CARLSSON, M ;
CARLSSON, A .
SCHIZOPHRENIA BULLETIN, 1990, 16 (03) :425-432
[17]  
COHEN R M, 1988, Journal of Nuclear Medicine, V29, P796
[18]   INCREASE IN RAT STRIATAL ACETYLCHOLINE CONTENT BY D-FENFLURAMINE, A SEROTONIN RELEASER [J].
CONSOLO, S ;
LADINSKY, H ;
TIRELLI, AS ;
CRUNELLI, V ;
SAMANIN, R ;
GARATTINI, S .
LIFE SCIENCES, 1979, 25 (23) :1975-1981
[19]   HIGH CENTRAL D2-DOPAMINE RECEPTOR OCCUPANCY AS ASSESSED WITH POSITRON EMISSION TOMOGRAPHY IN MEDICATED BUT THERAPY-RESISTANT SCHIZOPHRENIC-PATIENTS [J].
COPPENS, HJ ;
SLOOFF, CJ ;
PAANS, AMJ ;
WIEGMAN, T ;
VAALBURG, W ;
KORF, J .
BIOLOGICAL PSYCHIATRY, 1991, 29 (07) :629-634
[20]  
COYLE JT, 1969, SCIENCE, V166, P809